Every 8-K that Theravance Biopharma, Inc. (TBPH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow TBPH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TBPH filings page.
Theravance Biopharma, Inc. (TBPH) reported additional details about the pending merger with Zymeworks Inc. and voluntarily supplemented its definitive proxy statement for the September 18, 2026 shareholder meeting to approve the merger and related transactions.
The company describes an extensive sale process in 2025–2026 in which Lazard contacted 60 potential counterparties, 20 signed confidentiality agreements, 15 received management presentations and 12 conducted due diligence via a virtual data room. Lazard’s analysis used net debt of approximately $(385) million as of June 30, 2026 and about 54.9 million fully diluted ordinary shares, implying an equity value range of $15.25 to $16.25 per share. The filing also notes an amended engagement under which Evercore will receive a $7 million fee upon consummation of the merger.
The company discloses three shareholder complaints and 13 demand letters relating to alleged disclosure issues around the merger. While the company and other defendants deny the allegations and believe the matters are without merit, they are providing the supplemental disclosures to reduce litigation risk and avoid potential delay or disruption to the merger.
Theravance Biopharma, Inc. (TBPH) reported detailed Phase 3 CYPRESS Study 0197 results for ampreloxetine in patients with symptomatic neurogenic orthostatic hypotension associated with multiple system atrophy. The primary endpoint, change in OHSA composite score at week 8 during the double-blind randomized withdrawal period, was not statistically significant, and similar trends were seen in key secondary endpoints. Safety data from 129 open-label patients and 78 randomized-withdrawal patients showed ampreloxetine was generally well tolerated, with no deaths and limited serious adverse events. Post hoc analyses in a more narrowly defined symptomatic nOH population suggested coherent average treatment effects across OHSA, OHDAS and OHQ scores over weeks 2–8. After a Type B meeting in May 2026, the FDA indicated the existing data package would not support approval on its own but that an additional pivotal trial leveraging prior data could provide a potential path forward; the company has requested a Type C meeting to align on future study design.
Theravance Biopharma reported second-quarter 2026 results and progress on its pending sale to Zymeworks. Zymeworks has agreed to acquire the company for $17.00 per share in cash, plus a contingent value right (CVR) for 80% of net proceeds from any future ampreloxetine monetization over the next ten years, with closing targeted in the second half of 2026 subject to shareholder approval and customary conditions.
For the quarter ended June 30, 2026, total revenue was $20.7 million versus $26.2 million a year earlier. GAAP results showed a net loss of $5.9 million compared with net income of $54.8 million in the prior-year quarter, which had included large non-recurring gains. Non-GAAP net income was $9.5 million, improving from a non-GAAP net loss of $4.2 million. YUPELRI net sales (recorded by Viatris) were $70.7 million versus $66.3 million, implying $24.7 million for Theravance’s 35% share. Cash, cash equivalents and short-term marketable securities totaled $387.7 million at June 30, 2026. The company recorded $4.0 million of restructuring expenses and $6.1 million of transaction-related expenses in the quarter.
Theravance Biopharma has agreed to be acquired by Zymeworks in a cash-and-CVR deal. Zymeworks will buy Theravance Biopharma for $17.00 per share in cash, valuing the company at approximately $929 million, plus a contingent value right (CVR) tied to future monetization of the drug ampreloxetine.
Each CVR gives holders 80% of net proceeds from any license, divestiture or other monetization of ampreloxetine over ten years, plus a share of specified milestone and royalty payments as described in the CVR agreement. The price represents a 22% premium to the March 3, 2026 closing price and a 10% premium to the volume-weighted average price since that date. Closing is targeted for the second half of 2026, subject to shareholder approval, antitrust clearance and other customary conditions.
Theravance Biopharma, Inc. disclosed that its subsidiary Theravance Biopharma Ireland Limited entered into a compromise agreement with Dr. Áine Miller, Senior Vice President, Development and Head of the Ireland office. Under this agreement, her employment will terminate on November 15, 2026 as part of the restructuring announced in March 2026.
The agreement follows the terms of her existing employment contract, as amended in February 2026. The company will also make a $250,000 special pension contribution for Dr. Miller within 30 days after the termination date. In addition, on June 19, 2026, she received a grant of 18,750 restricted share units in connection with her continued service through the termination date.
Theravance Biopharma, Inc. reported the results of its 2026 Annual General Meeting of Shareholders held on June 12, 2026. Shareholders holding 47,059,878 ordinary shares, or 91.4% of shares entitled to vote, were present, providing a quorum to conduct business.
All director nominees, including Laurie Smaldone Alsup, Susannah Gray, Dean J. Mitchell, Donal O’Connor, Deepika R. Pakianathan, and Rick E. Winningham, were elected to serve until the 2027 annual meeting. Shareholders also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
In addition, shareholders approved a non-binding advisory resolution on the compensation of the company’s named executive officers, indicating overall support for the current executive pay program.
Theravance Biopharma reported improved first-quarter 2026 results and detailed a major restructuring to become a cash-generative, YUPELRI-focused company. Revenue rose to $17.7 million from $15.4 million, and the GAAP net loss narrowed to $4.9 million from $13.6 million. Non-GAAP results turned to a $0.6 million profit versus an $8.6 million loss a year earlier, helped by YUPELRI net sales of $62.4 million recorded by Viatris, of which Theravance’s implied 35% share was $21.9 million.
The company plans an organizational restructuring that winds down R&D, cuts G&A about 50% and is expected to reduce operating expenses by roughly 60% versus 2025 actuals of $111.1 million. Management targets about $70 million of full run-rate cost savings and approximately $60–70 million of annualized cash flow starting in the third quarter of 2026, excluding any potential $100 million TRELEGY milestone. Around 50% of the workforce will be affected, with $5–7 million of one-time cash severance costs. A Board Strategic Review Committee continues to evaluate alternatives, including a potential sale of the company.
Theravance Biopharma, Inc. announced a settlement of patent litigation over its YUPELRI® (revefenacin) inhalation solution. Theravance and its partner Mylan granted Mankind Pharma a royalty-free, non-exclusive license to sell a generic YUPELRI in the U.S. starting on the Licensed Launch Date of April 23, 2039, subject to customary exceptions.
The agreement resolves all pending Hatch-Waxman patent disputes related to YUPELRI. The settlement will be reviewed by the U.S. Department of Justice and the Federal Trade Commission, as required for patent settlements involving branded and generic drug makers.
Theravance Biopharma reported a sharp turnaround for 2025, with revenue rising to $107.5M from $64.4M and net income improving to $105.9M from a $56.4M loss in 2024. Q4 revenue was $45.9M and net income $61.0M.
YUPELRI® remained the core driver, with 2025 net sales of $266.6M (Viatris-reported) versus $238.6M in 2024. The company is winding down R&D, cutting G&A about 50%, and expects operating expenses to fall about 60% from 2025’s $111.1M, targeting $60–70M of annualized cash flow from Q3 2026.
A Board Strategic Review Committee of independent directors, advised by Lazard, is urgently evaluating alternatives, including a potential sale of the company, following the CYPRESS study not meeting its primary endpoint and the wind-down of the ampreloxetine program.
Theravance Biopharma reported that its Phase 3 CYPRESS trial of ampreloxetine in neurogenic orthostatic hypotension did not meet the primary OHSA composite endpoint, and the program will be wound down. The Board’s Strategic Review Committee is accelerating its evaluation of alternatives, including a possible sale of the company, with no assurance any transaction will occur.
The company announced a major restructuring that will eliminate its R&D organization, reduce G&A by about 50%, and cut operating expenses by roughly 60%, or about $70 million, impacting around half of the workforce. Management expects these actions, together with YUPELRI revenue, to support approximately $60–$70 million of annualized cash flow starting in Q3 2026.
Theravance highlighted cash of $326.5 million as of December 31 2025, expected cash of about $400 million at the end of Q1 2026 after receiving a $25 million YUPELRI milestone and a $50 million TRELEGY milestone, and a potential additional $100 million TRELEGY milestone tied to 2026 global sales. YUPELRI U.S. net sales reached $266.6 million in 2025, up 12% year over year.
Theravance Biopharma, Inc. filed a Form 8-K to furnish an investor presentation under Regulation FD. Members of the management team are holding one-on-one meetings with analysts and investors in San Francisco, California from January 12–15, 2026, using a corporate slide presentation. That slide deck, entitled “Corporate Presentation – January 2026”, is provided as Exhibit 99.1 and incorporated by reference into the report.
Theravance Biopharma (TBPH) furnished an 8-K announcing a press release and conference call covering financial results for the quarter ended September 30, 2025, along with a business update.
The materials include a press release (Exhibit 99.1) and a slide deck titled Third Quarter 2025 Financial Results and Business Update (Exhibit 99.2). The information in Item 2.02 and Item 9.01, including Exhibits 99.1 and 99.2, is being furnished and shall not be deemed filed under the Exchange Act.
Theravance Biopharma, Inc. reported that it has completed enrollment in the open-label portion of its pivotal Phase 3 CYPRESS study. This trial is evaluating a treatment in patients with symptomatic neurogenic orthostatic hypotension caused by multiple system atrophy.
The company described the study as pivotal and noted that all information related to this milestone is provided in a press release furnished as an exhibit. That press release is supplied for informational purposes and is not deemed filed under securities laws.
Theravance Biopharma, Inc. announced that its subsidiaries and partners Mylan Ireland Limited and Viatris Specialty L.P. have entered into a Settlement Agreement with Cipla Limited and Cipla USA, Inc. covering YUPELRI® (revefenacin) inhalation solution patents. The agreement resolves ongoing Hatch-Waxman patent litigation related to Cipla’s abbreviated new drug application for a generic YUPELRI® product in the United States.
Under the Settlement Agreement, Theravance and Mylan granted Cipla a royalty-free, non-exclusive, non-sublicensable, non-transferable license to manufacture and market Cipla’s generic version of YUPELRI® in the United States on or after the Licensed Launch Date of April 23, 2039, subject to customary exceptions. The settlement is subject to review by the U.S. Department of Justice and the Federal Trade Commission, and separate patent litigation remains pending against another ANDA filer, Mankind Pharma Ltd. and certain affiliates.
Theravance Biopharma notified investors that it has issued a press release and will hold a conference call presenting its financial results for the quarter ended June 30, 2025 and a business update.
The materials supporting the call are being furnished as Exhibit 99.1 (press release) and Exhibit 99.2 (slide deck). The filing states these exhibits are furnished and not filed, which limits certain statutory liabilities associated with filed disclosures.
Theravance Biopharma (NASDAQ: TBPH) filed an 8-K disclosing that China’s NMPA approved YUPELRI (revefenacin), the first once-daily nebulized LAMA for COPD in China.
The decision triggers a $7.5 million one-time milestone payment from partner Viatris, expected in Q3 2025, and entitles Theravance to additional sales-based milestones and tiered royalties on Chinese net sales. Viatris will fund and manage all development and commercialization activities.
No other financial statements were furnished; the disclosure is limited to Item 8.01 and Exhibit 99.1.